News Conference News HFSA 2022 New Dapagliflozin Insights: Early Benefits and Types of Deaths Prevented Todd Neale October 07, 2022
News Conference News HFSA 2022 Dapagliflozin’s Benefits Similar in HF Patients With Improved EF: DELIVER Todd Neale October 04, 2022
News Conference News ESC 2022 DELIVER Results, Other Analyses Bolster SGLT2 Inhibitors Across HF Spectrum Todd Neale August 27, 2022
News Daily News Myocarditis Risk Low Overall After COVID-19 Vax, but Higher in Some Groups Todd Neale August 23, 2022
News Opinion Editor's Corner ESC 2022 What’s Going to Be Hot at ESC 2022? Shelley Wood August 22, 2022
News Daily News Dapagliflozin Safe, Effective in Diabetes Regardless of Background CV Meds Shelley Wood July 25, 2022
News Daily News New Biomarker Data Again Draw Eyes to Mineral Oil in REDUCE-IT Caitlin E. Cox July 08, 2022
News Daily News Quadruple Therapy Costs Prohibitive for Many HFrEF Patients L.A. McKeown June 21, 2022
News Daily News Large Study Confirms Clot Risks With Oxford/AstraZeneca COVID-19 Vaccine Todd Neale June 15, 2022
News Conference News ESC Heart Failure 2022 Dapagliflozin Boosts Health Status Across LVEF Range Shelley Wood May 23, 2022
News Daily News Frailty Does Not Hinder Dapagliflozin’s HFrEF Impact: DAPA-HF Analysis Caitlin E. Cox May 03, 2022
News Daily News Clopidogrel Superior to ‘Divine’ Aspirin Monotherapy in Secondary Prevention Michael O'Riordan March 30, 2022